Pharmaceuticals Italy

Italy Plasma-Derived Therapies Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Italy Plasma-Derived Therapies Market Industry Trends and Forecast to 2034: Segmented by (Product, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Italy · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $824.6 Mn Placeholder estimate
Estimate 2025 $875.8 Mn 2.4% of the global market
Projected 2034 $1.50 Bn 71.8% Adds $629.1 Mn over 9 forecast years
CAGR 2025–2034 6.2% Faster than 32% of 180 Pharmaceuticals markets here
Key players 5
  • Italy is 2.39% of the global market.
  • In Europe, the largest is Germany at $1.49 Bn.
  • Fastest growing: Russia at 6.8% a year.
  • Italy ranks 4th of 6 by size in Europe.

Market size projection

Italy

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$629.1 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Plasma-Derived Therapies Market market size by year, Italy
YearMarket sizeChange that yearSince 2025
2024 (estimate) $824.6 Mn — —
2025 (base) $875.8 Mn +$51.1 Mn —
2026 (forecast) $930.1 Mn +$54.3 Mn +6.2%
2027 (forecast) $987.7 Mn +$57.7 Mn +12.8%
2028 (forecast) $1.05 Bn +$61.2 Mn +19.8%
2029 (forecast) $1.11 Bn +$65.0 Mn +27.2%
2030 (forecast) $1.18 Bn +$69.1 Mn +35.1%
2031 (forecast) $1.26 Bn +$73.4 Mn +43.5%
2032 (forecast) $1.33 Bn +$77.9 Mn +52.4%
2033 (forecast) $1.42 Bn +$82.7 Mn +61.8%
2034 (forecast) $1.50 Bn +$87.9 Mn +71.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Italy Plasma-Derived Therapies Market Analysis at a glance
Market size, 2025$875.8 Mn placeholder estimate
Forecast, 2034$1.50 Bn placeholder estimate
Growth (CAGR), 2025–20346.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, application and end user (see all)
Key playersCSL Behring, Takeda Pharmaceutical Company Ltd, Grifols, Octapharma, Kedrion Biopharma (see all)
Regulator in ItalyAIFASource: Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Italy Plasma-Derived Therapies Market Analysis Executive Summary

Plasma-derived therapies are medicines made from donated blood plasma, such as immunoglobulins, albumin and clotting factors.

Key segments of the plasma-Derived Therapies market include product (Immunoglobulins, Albumin and Coagulation Factors) and application (Immunology, Hematology and Critical Care).

Bar chart: Italy Plasma-Derived Therapies market size, 2024–2034, placeholder estimates. $824.6 Mn in 2024, $875.8 Mn in 2025 and $1.50 Bn in 2034, 6.2% CAGR.
Italy Plasma-Derived Therapies market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Italy Plasma-Derived Therapies Market Dynamics

Market Growth Drivers

More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the plasma-Derived Therapies market.

Opportunity

Ready-to-use formulations, biosimilars and supply security programmes give the plasma-Derived Therapies market room to grow.

Market Restraints

Drug shortages, price controls, generic competition and strict hospital budgets hold back the plasma-Derived Therapies market.

Competitive Landscape for Plasma-Derived Therapies Market in Italy

The plasma-Derived Therapies market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Plasma-Derived Therapies Market in Italy

Plasma-Derived Therapies in Italy: rules and payment

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AIFA, the Italian Medicines Agency, which also negotiates prices and reimbursement.⁠[1] The National Health Service (SSN), run by the regions, gives universal cover, and AIFA decides which medicines it pays for.⁠[2]

[1] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[2] Italian Ministry of Health. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for plasma-Derived Therapies. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Italy.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Plasma-Derived Therapies right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Plasma-Derived Therapies in context

Italy compared

  • Health spending per person: 3,398 US$ per person (2024). World: 1,317 US$ per person (2023). 4th highest of the 6 countries we cover in Europe.[1]
  • Doctors: 4.19 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 4th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 25.1% of people (2025). World: 10.4% of people (2025). Highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Plasma-Derived Therapies market in Italy?
Placeholder estimate: about $875.8 Mn in 2025, rising to about $1.50 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Plasma-Derived Therapies market in Italy growing?
Placeholder estimate: about 6.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Plasma-Derived Therapies market report cover?
The report splits the market by product (Immunoglobulins, Albumin, Coagulation Factors, Alpha-1 Antitrypsin), application (Immunology, Hematology, Critical Care, Neurology) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Plasma-Derived Therapies market?
Key players include CSL Behring, Takeda Pharmaceutical Company Ltd, Grifols, Octapharma and Kedrion Biopharma.
What is driving the Plasma-Derived Therapies market?
More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the plasma-Derived Therapies market.
Who regulates Plasma-Derived Therapies in Italy?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AIFA, the Italian Medicines Agency, which also negotiates prices and reimbursement. Source: Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
How is healthcare paid for in Italy?
The National Health Service (SSN), run by the regions, gives universal cover, and AIFA decides which medicines it pays for. Source: Italian Ministry of Health. Checked 14 Nov 2026.
How much research is published on Plasma-Derived Therapies?
PubMed lists 1,017 papers on Plasma-Derived Therapies added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Italy

See all

Related on biologics and biosimilars

See the topic